Highlights
- Second quarter revenue rose 33% to $28.1 million, and gross margin improved to 92% from 88% a year earlier.
- Net loss widened to $19.3 million, or $0.51 per share, from $13.6 million, or $0.38, a year earlier.
- Ceribell received a new FDA 510(k) clearance in June 2026 for two neurology algorithms, plus clearance of next-generation hardware.
- Ceribell signed a MidCap credit agreement on August 5, drew $20.0 million on the revolver and repaid its venture loan.
Ceribell (NASDAQ:CBLL) shares were trading near their 52-week high at USD 27.69 on October 21, 2026, up 0.04%. The medical technology company received a new FDA clearance in June, signed a new credit agreement on August 5, and filed its second quarter 2026 report on August 10.
Based in Sunnyvale, California, Ceribell was incorporated in Delaware in August 2014 as Brain Stethoscope, Inc., and took its current name in 2015. It develops a point-of-care electroencephalography platform that pairs portable disposable headbands and a pocket-sized recorder with AI-powered algorithms to help detect seizures and delirium in acute care settings. It sells Wearables and subscriptions and reports one segment. By June 30, 2026, more than 700 hospitals had adopted the system. Its fiscal year ends December 31.
Revenue Up 33% With Gross Margin Near 92%
Revenue for the quarter ended June 30, 2026 was $28.1 million, versus $21.2 million a year earlier. Product revenue grew 33% to $21.2 million and subscription revenue 30% to $6.9 million. Gross profit rose 39% to $25.9 million, a gross margin of 92% compared with 88%.
Operating expenses rose 37% to $45.9 million, with sales and marketing up 40% to $24.4 million, research and development up 39% to $6.7 million and general and administrative up 30% to $14.8 million. The loss from operations was $20.0 million, and the net loss was $19.3 million, or $0.51 per share, versus $13.6 million, or $0.38. For six months, revenue was $54.6 million, up 31%, and the net loss was $39.0 million versus $26.4 million.
Operating activities used $32.2 million of cash in the first half, versus $18.9 million a year earlier. The accumulated deficit was $259.4 million, and the company expects to keep incurring losses.
FDA Clearances, the MidCap Facility and the Natus Matter
In June 2026, Ceribell received a new FDA 510(k) clearance covering two neurology algorithms, EEG Artifact Reduction and Epileptiform Abnormality Detection, and said it also has FDA clearance on its full next-generation hardware platform, which it expects to support new indications. In December 2025, the FDA cleared its Delirium Monitor System, which the company describes as the first and only cleared delirium screening and monitoring device.
On August 5, 2026, Ceribell entered a credit agreement with MidCap Funding IV Trust as agent. It provides a $30.0 million term loan commitment, plus $25.0 million of uncommitted capacity at the lenders' discretion, and a revolving facility of up to $20.0 million, expandable to $30.0 million if conditions are met. At closing, the company borrowed $20.0 million on the revolver, drew nothing on the term loan and used the proceeds to repay its prior venture loan in full, which was then terminated.
Ceribell also remains in a patent dispute. It filed complaints against Natus Medical in July 2025, the U.S. International Trade Commission instituted an investigation in August 2025, and a related district court case is stayed. The company owes $2.9 million in deferred legal fees contingent on settlement or a favorable initial determination, and it has recorded no liability for that amount.
Liquidity and Outlook
Cash, cash equivalents and marketable securities were $129.3 million at June 30, 2026. Based on its operating plan, the company believes proceeds from its initial public offering, expected cash from customers and existing resources will fund planned operating and capital spending for at least the next 12 months, while cautioning that it may need more capital if its assumptions prove wrong.
The 10-Q gives no revenue or earnings guidance. Management says it intends to enlarge its direct sales organization in the United States, increase adoption and utilization of the Ceribell System, and invest in research and development to extend the platform to other neurological conditions.






Please wait processing your request...